DermTech, Inc. announced an agreement with a Blues plan in Hawaii. The contract, which is in addition to a favorable coverage policy, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the nearly 800,000 members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99% negative predictive value (NPV).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.39 USD | +6.53% | -21.92% | -77.71% |
14/05 | Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M | MT |
22/04 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-77.71% | 13.5M | |
-4.92% | 12.27B | |
-5.82% | 7.99B | |
+5.43% | 5.69B | |
+26.16% | 5.42B | |
-9.58% | 4.13B | |
-59.63% | 2.7B | |
+8.44% | 2.6B | |
-3.70% | 2.38B | |
+21.00% | 2.1B |
- Stock Market
- Equities
- DMTK Stock
- News DermTech, Inc.
- DermTech, Inc. Announces Contract with Hawaii Blues Plan for the Foundational Assay of Its Dermtech Melanoma Test